Kilickap, S.Sezer, A.Gumus, M.Bondarenko, I.Ozguroglu, M.Gogishvili, M.Turk, H. M.Cicin, I.Bentsion, D.Gladkov, O.Clingan, P.Sriuranpong, V.Rizvi, N.Li, S.Lee, S.Makharadze, T.Paydas, S.Nechaeva, M.Seebach, F.Weinreich, D.M.Yancopoulos, G.D.Gullo, G.Lowy, I.Rietschel, P.2022-09-132022-09-1320211556-0864http://hdl.handle.net/11727/7719enginfo:eu-repo/semantics/closedAccessnon-small cell lung canceranti-PD-1cemiplimabClinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLCconferenceObject163S101S101000631349600072